AlphaQuest LLC Trims Holdings in Phreesia, Inc. (NYSE:PHR)

AlphaQuest LLC lessened its position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 93.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,081 shares of the company's stock after selling 29,215 shares during the period. AlphaQuest LLC's holdings in Phreesia were worth $52,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in PHR. The Manufacturers Life Insurance Company raised its holdings in Phreesia by 3.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company's stock valued at $637,000 after buying an additional 905 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Phreesia by 3.8% during the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company's stock valued at $701,000 after acquiring an additional 1,120 shares during the last quarter. R Squared Ltd acquired a new position in shares of Phreesia during the fourth quarter worth $30,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Phreesia by 9.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company's stock worth $319,000 after purchasing an additional 1,258 shares during the last quarter. Finally, BankPlus Trust Department acquired a new stake in Phreesia in the fourth quarter valued at $34,000. 92.10% of the stock is currently owned by institutional investors.

Insider Transactions at Phreesia

In other Phreesia news, SVP Amy Beth Vanduyn sold 1,311 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $26.61, for a total transaction of $34,885.71. Following the transaction, the senior vice president now directly owns 115,633 shares in the company, valued at $3,076,994.13. This trade represents a 1.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Evan Roberts sold 2,873 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $26.61, for a total transaction of $76,450.53. Following the completion of the sale, the chief operating officer now owns 779,993 shares of the company's stock, valued at approximately $20,755,613.73. The trade was a 0.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 162,442 shares of company stock worth $4,611,300. 5.80% of the stock is currently owned by corporate insiders.

Remove Ads

Phreesia Price Performance

Phreesia stock traded up $0.65 during mid-day trading on Monday, hitting $28.11. 556,397 shares of the company traded hands, compared to its average volume of 417,221. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -19.12 and a beta of 1.03. The stock has a fifty day moving average price of $27.33 and a 200-day moving average price of $24.07.

Analyst Upgrades and Downgrades

PHR has been the subject of several analyst reports. Truist Financial raised their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Canaccord Genuity Group upped their target price on Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Citigroup lifted their target price on Phreesia from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, January 10th. Needham & Company LLC restated a "buy" rating and set a $29.00 price target on shares of Phreesia in a report on Thursday, March 13th. Finally, Royal Bank of Canada upgraded shares of Phreesia from a "sector perform" rating to an "outperform" rating and lifted their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, Phreesia presently has an average rating of "Buy" and an average price target of $31.33.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.